SCHEMBL30891325

SCHEMBL30891325

O=C(CCCCCNC(=O)OCc1ccccc1)NCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.46
▸ LMNA P02545 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ MMP13 P45452 1/20 0.45
▸ TGM2 P21980 1/20 0.44
▸ MAOB P27338 1/20 0.44
▸ LGALS8 O00214 1/20 0.42
▸ SIRT2 Q8IXJ6 2/20 0.42
▸ HDAC3 O15379 1/20 0.41
▸ HDAC4 P56524 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC7 Q8WUI4 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ HDAC10 Q969S8 1/20 0.41
▸ HDAC11 Q96DB2 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ HDAC9 Q9UKV0 1/20 0.41
▸ HDAC5 Q9UQL6 1/20 0.41
▸ NCOR2 Q9Y618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30391620 1.00 HTT (0.46) HTTLMNASMN1; SMN2MMP13TGM2
SCHEMBL30391887 0.93 MMP13 (0.45) HTTLMNASMN1; SMN2MMP13TGM2
SCHEMBL30891312 0.91 MMP13 (0.46) HTTLMNASMN1; SMN2MMP13TGM2
SCHEMBL29880337 0.91 MMP13 (0.46) HTTLMNASMN1; SMN2MMP13TGM2
SCHEMBL30891369 0.91 MMP13 (0.46) HTTLMNASMN1; SMN2MMP13TGM2
SCHEMBL30391867 0.91 LMNA (0.43) HTTLMNASMN1; SMN2MMP13TGM2
SCHEMBL13256301 0.91 MMP13 (0.44) HTTLMNASMN1; SMN2MMP13TGM2
SCHEMBL17109659 0.91 MMP13 (0.44) HTTLMNASMN1; SMN2MMP13TGM2
SCHEMBL8985399 0.91 TGM2 (0.49) HTTLMNASMN1; SMN2TGM2MAOB
SCHEMBL28333071 0.91 LMNA (0.54) HTTLMNASMN1; SMN2MAOBLGALS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2026-01-22 — — US disclosed
EP-4615487-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES Merck Sharp & Dohme LLC (US) 2025-09-17 — — EP disclosed
WO-2024102633-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2024-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES INSR, GPR119, GLP1R HTT 1719/4885LMNA 4564/4885SMN1; SMN2 1622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback